Oxurion
ActiveSummary
The computed 12-month bankruptcy probability of Oxurion is 3.0% (moderate). The 2025 annual accounts show negative equity (-€12.2m) and a net result of -€3.2m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 5% of 3,821 sector peers (NACE 70, financial year 2025). The company has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
3 holdingsHoldings 3
Source for every holding own accounts 2025
- OncurioussubsidiaryEquity €90,265Result -€6,278100%
- Oxurion FranceFRsubsidiaryEquity -€17,546Result -€22,546100%
- ThromboGenics Inc.USsubsidiaryEquity USD 1.9mResult -USD 6,008100%
According to the 2025 annual accounts of Oxurion and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.